Ironwood Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; financial statements are unaudited. Ironwood is a GI-focused healthcare company whose principal commercial product is LINZESS, marketed in the U.S. in partnership with AbbVie. Reported revenue is primarily collaboration and license revenue, including Ironwood’s share of U.S. LINZESS profits.
Key financial metrics
Amounts are in millions of dollars except per-share data and percentages.
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Total revenue | $88.8 | $79.9 | +$8.9, or 11% |
| Collaborative arrangements revenue | $88.7 | $74.4 | +$14.2, or 19% |
| Operating income | $45.4 | $13.2 | +$32.2 |
| Operating margin | 51.1% | 16.5% | +34.6 percentage points |
| Net income | $39.9 | $3.3 | +$36.6 |
| Net margin | 45.0% | 4.2% | +40.8 percentage points |
| Diluted earnings per share | $0.25 | $0.02 | +$0.23 |
| Net cash from operating activities | $73.7 | $43.6 | +$30.1 |
- Cash and cash equivalents were $438.5 million at March 31, 2021, up from $362.6 million at year-end 2020. Including restricted cash, period-end cash totaled $440.7 million.
- Current assets were $538.2 million and current liabilities $23.6 million, indicating substantial reported short-term liquidity.
- Convertible notes had $520.7 million aggregate principal outstanding and a $436.1 million net carrying amount. Notes mature between 2022 and 2026; the 2022 notes mature in June 2022. Operating lease liabilities totaled $23.0 million.
- Capital expenditures were zero in Q1 2021, versus $1.4 million in Q1 2020. Financing cash flow was $2.2 million, mainly from employee stock-plan proceeds.
Material changes versus Q1 2020
- U.S. LINZESS collaboration revenue increased $14.8 million, attributed to increased prescription demand and inventory fluctuations, partly offset by lower net price. Ironwood’s U.S. collaboration revenue was $85.9 million.
- API revenue fell $5.3 million to $0.2 million, largely because AstraZeneca assumed China commercial supply responsibilities in 2020.
- Research and development expense declined 45% to $15.5 million, primarily reflecting lower IW-3718 development costs after the program was discontinued. Early research and development spending increased.
- Selling, general and administrative expense declined 24% to $27.7 million, mainly due to lower compensation, marketing and travel costs. Total expenses fell 35% to $43.4 million.
- Other expense, net improved to $5.0 million from $9.9 million, including a $2.4 million derivative gain versus a $3.5 million derivative loss a year earlier. These fair-value movements are noncash and contributed to the year-over-year earnings comparison.
Outlook, management commentary and risks
- Management said cash on hand should fund projected operating needs for at least the next 12 months from issuance of the financial statements. It also cautioned that estimates depend on assumptions and actual results could use available capital sooner than expected. No numerical revenue or earnings guidance is provided in the filing.
- Ironwood expects U.S. LINZESS collaboration revenue to remain a significant portion of total revenue and expects substantial expenses to continue as it commercializes LINZESS and invests in development and pipeline opportunities. Q1 results are not necessarily indicative of full-year results.
- The company reported an accumulated deficit of approximately $1.4 billion and stated it cannot guarantee continued positive cash flows. Its business is highly dependent on LINZESS demand, pricing and reimbursement, and execution with AbbVie; reported U.S. collaboration revenue also depends on partner-provided sales and expense information.
- COVID-19 could affect promotion, patient access, reimbursement, clinical development and supply chains. As of the filing date, the company reported no significant COVID-related disruption to U.S. LINZESS manufacturing or supply, while noting continuing uncertainty.
- Development setbacks include discontinued MD-7246 after a Phase II trial missed key endpoints and discontinued IW-3718 after a Phase III trial failed its primary endpoint. Pediatric LINZESS studies and post-approval requirements remain ongoing. Competition, generic challenges, patent litigation, partner reliance and manufacturing capacity are additional risks.
- Ironwood recorded $0.3 million of restructuring expense in Q1 related to the prior workforce reduction. On May 4, 2021, after quarter-end, the board authorized repurchases of up to $150 million of common stock through December 31, 2022; repurchases are discretionary and subject to market and other factors.
- Mark Mallon resigned as CEO effective March 12, 2021; President Thomas McCourt became interim CEO. Management reported disclosure controls were effective and no other material change to internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether LINZESS prescription demand, net pricing and inventory patterns support continued growth in Ironwood’s U.S. collaboration revenue.
- How much of reported cash generation reflects recurring operating performance versus working-capital movements, including the reduction in receivables.
- The company’s ability to meet the 2022 convertible-note maturity and other debt obligations while funding operations and any share repurchases.
- Progress and spending priorities for the remaining pipeline, including linaclotide pediatric programs and early-stage GI research, following the discontinued programs.
- Developments in generic LINZESS challenges, patent protection, reimbursement and the company’s dependence on AbbVie and other commercialization and supply partners.
- Whether COVID-19, leadership transition or changes in promotion and healthcare access materially affect demand, clinical activity or operating costs.